NUTRIBAND INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.89 USD | -1.67% |
|
+11.34% | +153.88% |
| Jun. 20 | Nutriband Inc. Provides Product Development Update for its Lead Product Aversa Fentanyl | CI |
| May. 31 | Nutriband Inc. Reports Earnings Results for the First Quarter Ended April 30, 2024 | CI |
Financials (USD)
| Sales 2023 | 2.08M | Sales 2024 | 2.09M | Capitalization | 22.08M |
|---|---|---|---|---|---|
| Net income 2023 | -4M | Net income 2024 | -5M | EV / Sales 2023 | 12.9 x |
| Net cash position 2023 | 1.8M | Net cash position 2024 | 252K | EV / Sales 2024 | 10.5 x |
| P/E ratio 2023 |
-6.89
x | P/E ratio 2024 |
-3.78
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 |
-
| Free-Float | 55.32% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.67% | ||
| 1 week | +11.34% | ||
| Current month | +9.07% | ||
| 1 month | +8.07% | ||
| 3 months | +16.40% | ||
| 6 months | +154.53% | ||
| Current year | +153.88% |
1 week
5.25
6.05
1 month
4.706.60
Current year
2.226.75
1 year
1.536.75
3 years
1.5312.86
5 years
0.8634.29
10 years
0.8643.54
| Managers | Title | Age | Since |
|---|---|---|---|
Gareth Sheridan
FOU | Founder | 35 | 11-12-31 |
Serguei Melnik
FOU | Founder | 52 | 11-12-31 |
Gerald Goodman
DFI | Director of Finance/CFO | 76 | 18-07-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Serguei Melnik
FOU | Founder | 52 | 11-12-31 |
Stefan Mancas
BRD | Director/Board Member | 48 | 18-06-30 |
Gareth Sheridan
FOU | Founder | 35 | 11-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 5.89 | -1.67% | 34,579 |
| 24-07-01 | 5.99 | +10.93% | 31,992 |
| 24-06-28 | 5.4 | +1.12% | 26,492 |
| 24-06-27 | 5.34 | -1.11% | 10,529 |
| 24-06-26 | 5.4 | +2.08% | 17,544 |
Delayed Quote OTC Markets, July 02, 2024 at 04:00 pm EDT
More quotes
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Calendar
2024-08-29
- Q2 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +153.88% | 65M | |
| -6.24% | 180B | |
| -6.08% | 99.21B | |
| -5.98% | 66.25B | |
| -9.35% | 44.74B | |
| +8.34% | 43.82B | |
| +10.35% | 41.96B | |
| +11.88% | 28.98B | |
| -8.38% | 23.5B | |
| +16.18% | 24.07B |
- Stock Market
- Equities
- NTRB Stock
